120 related articles for article (PubMed ID: 9469361)
1. Metastatic germ cell tumors: modeling for response to chemotherapy.
Bajorin DF; Mazumdar M; Meyers M; Motzer RJ; Vlamis V; Lin P; Bosl GJ
J Clin Oncol; 1998 Feb; 16(2):707-15. PubMed ID: 9469361
[TBL] [Abstract][Full Text] [Related]
2. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
3. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
[TBL] [Abstract][Full Text] [Related]
4. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
6. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
7. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
8. Mediastinal germ cell tumors. A continuing odyssey.
Golbey RB
Chest Surg Clin N Am; 1994 Feb; 4(1):195-200. PubMed ID: 7519959
[TBL] [Abstract][Full Text] [Related]
9. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
Bokemeyer C; Nichols CR; Droz JP; Schmoll HJ; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Hartmann JT
J Clin Oncol; 2002 Apr; 20(7):1864-73. PubMed ID: 11919246
[TBL] [Abstract][Full Text] [Related]
10. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma.
Fosså A; Fosså SD
Br J Urol; 1989 Apr; 63(4):408-15. PubMed ID: 2653557
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.
Saxman SB; Finch D; Gonin R; Einhorn LH
J Clin Oncol; 1998 Feb; 16(2):702-6. PubMed ID: 9469360
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
13. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
14. The management of patients with advanced germ cell tumors. Seminoma and nonseminoma.
Law TM; Motzer RJ; Bajorin DF; Bosl GJ
Urol Clin North Am; 1994 Nov; 21(4):773-83. PubMed ID: 7974906
[TBL] [Abstract][Full Text] [Related]
15. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
16. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C; Kollmannsberger C; Meisner C; Harstrick A; Beyer J; Metzner B; Hartmann JT; Schmoll HJ; Einhorn L; Kanz L; Nichols C
J Clin Oncol; 1999 Nov; 17(11):3450-6. PubMed ID: 10550141
[TBL] [Abstract][Full Text] [Related]
17. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ-cell tumors with high levels of HCG.
Shinoda J; Sakai N; Yano H; Hattori T; Ohkuma A; Sakaguchi H
J Neurooncol; 2004 Jan; 66(1-2):225-40. PubMed ID: 15015791
[TBL] [Abstract][Full Text] [Related]
19. Germ cell tumors: staging, prognosis, and outcome.
Prow DM
Semin Urol Oncol; 1998 May; 16(2):82-93. PubMed ID: 9649231
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotropin detection in cerebrospinal fluid of patients with a germinoma and its prognostic significance: assessment by using a highly sensitive enzyme immunoassay.
Fukuoka K; Yanagisawa T; Suzuki T; Shirahata M; Adachi JI; Mishima K; Fujimaki T; Katakami H; Matsutani M; Nishikawa R
J Neurosurg Pediatr; 2016 Nov; 18(5):573-577. PubMed ID: 27391806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
